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Background: HPTN 046 compared the efficacy and safety of
infant nevirapine (NVP) among HIV-exposed breastfed infants
randomized at 6 weeks to 6 months to t NVP or placebo to prevent
postnatal infection: we report final 18-month outcomes.
Methods: Randomized, placebo-controlled trial in 4 African
countries. Infant diagnostic HIV testing was performed regularly
from birth through 18 months. Kaplan–Meier analysis was used to
assess 18-month cumulative infant HIV infection, HIV infection/or
death, and mortality rates.
Results: Between 6 weeks and 6 months, postnatal HIV infection rates
were significantly lower among infants receiving daily NVP from 6
weeks to 6 months 1.1% [95% confidence interval (CI): 0.2% to 1.8%],
compared with placebo 2.4% (95% CI: 1.3% to 2.6%), P = 0.049, but
not significantly lower thereafter. Eighteen-month postnatal infection
rates were low: 2.2% (95% CI: 1.1% to 3.3%) versus 3.1% (95% CI:
1.9% to 4.4%), respectively, P = 0.28. Mortality and HIV infection/death
did not differ between arms at any age. Infants of women receiving
antiretroviral therapy (ART) for their own health had the lowest 18-
month postnatal infection rates (0.5%, 95% CI: 0.0% to 1.1%). How-
ever, HIV infection/death rates at 18 months were not significantly
different for infants of mothers on ART (3.7%, 95% CI: 1.9% to
5.5%), and infants of mothers with CD4 counts of $350 cells per cubic
millimeter not receiving ART (4.8%, 95% CI: 2.7% to 6.8%; P = 0.46).
There were no differences in adverse events between study arms.
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Conclusions: This trial demonstrated early but not late differences
in postnatal HIV transmission among infants randomized at age 6
weeks to extended NVP or placebo, underscoring the importance of
continued prophylaxis throughout breastfeeding.
Key Words: nevirapine, infant HIV prophylaxis, PMTCT
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INTRODUCTION
In high HIV-prevalence resource-limited settings,
breastfeeding is critical to child survival but also carries the
risk of HIV transmission for HIV-exposed infants. In 2011,
UNAIDS estimated that 330,000 infants were infected with
HIV, one-third of these occurring during breastfeeding.1 The
global health goal is to find strategies that optimize breast-
feeding benefits while reducing the risk of HIV transmission
during breastfeeding.
Toward this goal, several recent randomized clinical
trials conducted among HIV-infected breastfeeding women
demonstrated the efficacy of either maternal triple antiretro-
viral (ARV) drug prophylaxis or infant ARV prophylaxis for
up to 28 weeks of breastfeeding.2–6
Revised World Health Organization (WHO) guidelines
in 2009–2010 recommended exclusive breastfeeding through 6
months with extended breastfeeding through 12 months for
HIV-exposed infants; and several ARV options for prevention
of mother to child transmission (PMTCT) extrapolated from
the above PMTCT prophylaxis trials.7,8 These options included
option A: maternal zidovudine (AZT) starting as early as 14
weeks gestation followed by daily infant nevirapine (NVP)
continuing until 1 week postcessation of breastfeeding; option
B: maternal triple ARV prophylaxis during pregnancy and until
1 week postcessation of breastfeeding; or based on updated
2012–2013 WHO guidelines, option B+ with lifetime contin-
uation of ART for all pregnant HIV-infected women.9,10
Among the infant based PMTCT prophylaxis trials, HPTN
046 was the only trial designed to test the relative efficacy and
safety of extended once daily infant NVP prophylaxis to 6
months among breastfed HIV-exposed infants who had received
6 weeks of NVP and were uninfected at age 6 weeks. The trial
was implemented during a time when breastfeeding was
recommended to stop by 6 months for HIV-exposed infants.
Early results from HPTN 046 have been reported and
demonstrated a significant reduction in postnatal transmission at
age 6 months with the longer infant NVP regimen and no short-
term safety concerns.11 The aim of these analyses was to look at
longer-term safety and late 18-month efficacy of the 6 months
versus 6 weeks of infant NVP among HIV-exposed infants
whose mothers were counseled to stop breastfeeding at 6 months.
This article presents final HIV transmission, infant HIV-free sur-
vival, and overall infant survival through age 18 months, as well
as cumulative adverse events (AEs) by study arm after discon-
tinuation of infant study drug prophylaxis at 6 months.
METHODS
HPTN 046 was a phase 3, randomized, double-blind,
placebo-controlled trial that assessed the efficacy and safety of
extension of once-daily NVP to 6 months of age or until
cessation of breastfeeding (whichever came first) for prevention
of HIV transmission in HIV-1–exposed breastfeeding infants
who had received NVP prophylaxis until 6 weeks of age. Eli-
gible HIV-uninfected infants were then randomized to receive
either extended daily NVP or placebo using age-adjusted doses
through 6 months or end of breastfeeding, whichever occurred
earlier. As per WHO and Ministries of Health recommendations
at the time of the trial design, HIV-infected mothers were coun-
seled to stop breastfeeding at about 6 months over a short time
period. Both regimens exceeded country PMTCT guidelines in
the sites at the time the study was implemented.
Study Population
HIV-infected mothers were recruited at trial sites in
South Africa, Tanzania, Uganda, and Zimbabwe. Interested
HIV-infected women aged $18 years without other serious
illness who intended to breastfeed were consented and screened
either during the third trimester or up through 7 days postpar-
tum. There were no restrictions to entry based on maternal CD4
counts, and women could have received either ARVs solely for
PMTCT or for treatment. Written informed consent was
obtained from HIV-infected eligible mothers. Eligible women
and their infants were enrolled within 7 days of delivery. In-
fants were eligible if HIV-uninfected based on an HIV DNA
polymerase chain reaction (PCR) negative from specimen ob-
tained within 7 days of birth, birth weight of $2000 g, without
life-threatening conditions and breastfeeding. Infant follow-up
study visits were scheduled at 2, 5, 6, and 8 weeks, and at 3, 6,
9, 12, and 18 months. Enrolled women were counseled to
exclusively breastfeed for 6 months, and then wean rapidly
with introduction of breast milk substitutes and complementary
foods. A detailed description of the HPTN 046 study design has
been previously reported.11 The trial registration number is
NCT00074412 under clinicaltrials.gov registry, and the imple-
mented study protocol can be accessed at www.HPTN.org.
Study recruitment into version 3.0 of HPTN 046 began
in May 2008 after protocol approval by all relevant Institu-
tional Review Boards and regulatory bodies in the respective
countries. Eighteen-month infant follow-up was completed in
September 2011.
Randomization and Masking
All enrolled infants received once-daily open-label
NVP (10 mg/mL oral suspension) for the first 6 weeks of
life. After the initial 6-week NVP prophylaxis regimen, at
between 6 and 8 weeks, eligible infants were randomized in
a one-to-one ratio to receive extended NVP (treatment arm) or
placebo (control arm) according to computer-generated
permutated block algorithms by site with random block sizes.
Infants were also stratified by maternal ART use at random-
ization. Study staff and participants were masked to the study
product (NVP or placebo) assignment.
Procedures
For infants randomized at 6 weeks, real-time PCR
HIV-1 testing was performed at 3, 6, 9, and 12 months, and
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EIA or rapid HIV antibody test at 18 months. An infant was
considered HIV-1 infected at months 3 through 12, if 2
separate blood specimens taken at different times were
positive by HIV-1 DNA PCR (Roche AMPLICOR HIV-1
DNA Test, Version 1.5) or quantitative HIV-1 RNA PCR, if
HIV-1 DNA PCR was not available. An infant was consid-
ered HIV-1–infected at month 18, if 2 separate blood speci-
mens taken at different times were positive by HIV EIA or
rapid testing and confirmed by HIV-1 Western blot (Bio-Rad
Laboratories Genetic Systems HIV-1 Western Blot). Infant
stored specimens collected at randomization were tested ret-
rospectively if the infant had a positive PCR test at the
3-month visit; those infants found to have a positive test at
randomization were excluded from the analyses. All infants
received cotrimoxazole as standard of care according to their
country guidelines.
FIGURE 1. Study design and participant follow-up.
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All AEs were captured through 8 months of infant life
(8 weeks after the maximum study drug dosing duration) and
thereafter through 18 months, only if considered serious or
meeting criteria for expedited reporting. We graded clinical
and laboratory AEs according to the DAIDS Table for
grading the severity of adult and pediatric AEs (Version
1.0, December 2004, with Clarification dated August 2009).12
Final primary study end points included cumulative
infant HIV-1 infection at age 18 months among infants who
were uninfected at age 6 weeks and relative rates of HIV-1
infection over 18 months, HIV-free and overall survival at 18
months, and cumulative frequency and severity of AEs by 18
months. Adherence to study product was based on maternal
self-report.
Statistical Analysis
Sample size determination and statistical methods are
described in detail elsewhere.11 Means and proportions were
used to summarize baseline characteristics. The Kaplan–Meier
method was used to calculate rates of cumulative HIV-1 infec-
tion, death, and HIV-free survival by randomization arm at 6,
9, 12, and 18 months among infants uninfected at 6 weeks of
age, and Greenwood formula was used to calculate standard
errors at the defined time points. We used a Z statistic to
compare the calculated rates at each time point. For the
Kaplan–Meier cumulative-infection analysis, time to HIV-1
infection was defined as the midpoint between the last negative
and first positive test. We censored infants with no positive
tests at the time of the last negative test. For HIV-free survival,
the event time was the minimum of the infection time and the
death time with censoring at the last negative test if no positive
test or death was observed.
To better understand the impact of extended infant NVP
prophylaxis on transmission risk, in the presence or absence of
maternal ART; we also conducted post hoc exploratory non-
randomized subgroup analyses. For these subgroup analyses, we
assessed subgroups defined by maternal ART use and maternal
CD4 counts (,350/$350 cells/mm3) at the time of randomiza-
tion. Using the same statistical methods, an exploratory analysis
was also performed to compare rates of death and/or HIV-free
survival between infants born to mothers who were on ART at
randomization, and infants who were randomized to the NVP
arm whose mothers were not on ART and had CD4 counts of
$350 cells per cubic millimeter at randomization.
Role of the Funding Source
The sponsor (US National Institutes of Health) partic-
ipated in the design and oversight of the study, interpretation
of the results, and preparation of the article. The sponsor also
provided for an independent data and safety monitoring board
to review the trial safety and efficacy at regular intervals.
Members of the writing team had full access to the study data.
The protocol chair, co-chairs, and sponsor representatives had
final responsibility for submission for publication.
RESULTS
Between June 2008 and March 2010, 1527 infants were
randomized at age 6 weeks (following 6 week open-label
daily NVP). Five infants (3 in NVP and 2 in placebo arm)
who were later found to have a positive HIV-1 DNA PCR
tested retrospectively on stored blood from age 6 weeks were
excluded from the analysis. This left 1522 infants included in
the primary analyses: 759 infants for the primary analyses in
TABLE 1. Cumulative 18-Month HIV-1 Infection, Death, or Both in Infants Uninfected at Age 6 Weeks
Study End Point (at .6
wk in Infants Uninfected
at 6 wk)










Point (%)* (95% CI)
All randomized infants
HIV-1 infection
6 mo 8/700 1.1 (0.3 to 1.8) 18/698 2.4 (1.3 to 3.6) 54 0.049
9 mo 11/692 1.5 (0.6 to 2.4) 21/683 2.9 (1.7 to 4.1) 48 0.078
12 mo 15/670 2.1 (1.0 to 3.1) 22/667 3.0 (1.8 to 4.2) 30 0.265
18 mo 16/664 2.2 (1.1 to 3.3) 23/663 3.1 (1.9 to 4.4) 29 0.280
Death
6 mo 9/716 1.2 (0.4 to 2.0) 8/725 1.1 (0.3 to 1.8) 0 0.805
9 mo 16/703 2.2 (1.1 to 3.2) 19/705 2.6 (1.4 to 3.7) 15 0.612
12 mo 20/688 2.7 (1.6 to 4.0) 26/690 3.5 (2.2 to 4.9) 23 0.373
18 mo 26/678 4.7 (2.0 to 7.4) 30/684 4.1 (2.7 to 5.6) 215 0.719
HIV-1infection or death
6 mo 17/706 2.3 (1.2 to 3.4) 24/707 3.2 (2.0 to 4.5) 28 0.274
9 mo 26/693 3.6 (2.2 to 4.9) 39/687 5.3 (3.7 to 6.9) 32 0.104
12 mo 32/676 4.5 (3.0 to 6.0) 46/669 6.3 (4.6 to 8.1) 29 0.111
18 mo 39/668 5.5 (3.8 to 7.1) 49/665 6.7 (4.9 to 8.5) 18 0.323
*Cumulative rates at 6, 9, 12, and 18 months calculated using Kaplan–Meier methods.
†Two-sided P value for Z statistic of the difference in probabilities.
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the NVP arm and 763 infants in the placebo arm (Fig. 1).
Maternal and infant demographics and maternal clinical status
were similar across the 2 study arms at randomization: median
maternal age was 27 years and median infant birth weight was
3100 g in both study product arms; 96% and 97% of women
were WHO clinical stage I or II and median CD4 count was
560 (range, 53–2172) and 528 (range, 49–1962) cells per cubic
millimeter in the NVP and placebo arms, respectively. Four
hundred thirty-nine (29%) mothers were receiving ART for
their own health at the 6-week randomization visit, 220/752
(29%) on the NVP arm and 219/753 (29%) on the placebo arm.
Fifty-two percent of infants in each study arm were men.11
During the 6-week to 18-month follow-up period
among randomized infants, there were 56 infant deaths, 26
in the NVP and 30 in the placebo arms. Excluding deaths,
overall loss to follow-up at 18 months was low across both
FIGURE 2. A, Proportion of infants
HIV-free. B, Proportion of infants
alive and HIV-free. C, Proportion of
infants alive.
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study arms: 58/759 (7.6%) in the NPV arm were lost to
follow-up excluding deaths, and 52/763 (6.8%) in the placebo
arm. Maternal report of adherence to giving infant NVP was
high. Across all visits, 88%–96% of mothers reported that
their infants had missed no study product doses since the last
visit, with no significant differences by study arm.
Cumulative Transmission, HIV or Death, and
Overall Mortality Through 18 Months
Cumulative postnatal infant HIV infection, HIV infec-
tion/mortality rates, and overall mortality between age 6
weeks and 18 months are shown in Table 1 and presented as
HIV-free, HIV-free survival, and overall 18-month survival
rates in Figures 2A–C. There were 39 postnatal HIV infec-
tions occurring between 6 weeks and 18 months. As reported
earlier, HIV infection rates after age 6 weeks were low but
significantly different at 6 months between study arms: 1.1%
[95% confidence interval (CI): 0.3% to 1.8%] in the NVP arm
versus 2.4% (95% CI: 1.3% to 3.6%) in the placebo arm, P =
0.049. However, after discontinuation of study product at 6
months, HIV infection rates were no longer significantly dif-
ferent from 9 through 18 months. By 18 months, there were
16 infections in the NVP arm versus 23 infections in the
placebo arm, with a cumulative postnatal infection rate of
2.2% (95% CI: 1.1% to 3.3%) versus 3.1% (95% CI: 1.9%
to 4.4%, P = 0.28), translating into HIV-free rates of 97.8% in
the NVP arm versus 96.9% in the placebo arm (Fig. 2A).
Median duration of breastfeeding was 184 days in both
study arms reflecting WHO guidelines at that time for HIV-
infected mothers; by 12 months, 95% of infants had reported
cessation of breastfeeding. A total of 14/39 (36%) of infections
occurred after age 6 months; 7/39 (18%) infections (5 in the
NVP arm and 2 in the placebo arm) were first detected between
the ages 9 and 18 months, among infants with at least 1 negative
PCR result recorded after reported cessation of breastfeeding.
Cumulative HIV-free survival rates between 6 weeks
and 18 months are presented in Figure 2B; rates were not
significantly different between study arms at 6, 9, 12, or 18
months although there was a nonsignificant trend for higher
risk of HIV infection and/or death among infants receiving
placebo compared with NVP. The 18-month cumulative HIV-
free survival rate was high: 94.5% (95% CI: 92.9% to 96.2%)
in the NVP arm and 93.3% (95% CI: 91.5% to 95.1%) in the
placebo arm (P = 0.32). Likewise, overall infant survival rates
at 18 months (Fig. 2C) were not statistically different between
study arms: 95.3% (95% CI: 92.6% to 98.0%) for NVP versus
95.9% (95% CI: 94.4% to 97.3%) for placebo (P = 0.72).
Post Hoc Subgroup Analyses: Rates of HIV
Infection and HIV/Death by Maternal ART
and CD4 Cell Subgroups
In addition to the primary late outcomes, we calculated
rates of infection for women by immune status and HIV
treatment status to better understand the impact of infant NVP
TABLE 2. AEs, Selected Grade 3 or Higher Laboratory Abnormalities, and Rash AEs Overall and by Study Arm, Among
Randomized Infants Who Were Exposed to Study Product (NVP or Placebo)
Nevirapine Placebo Total P
No. infants who initiated study product 758 761 1519 —
AEs
Infants with at least 1 AE 629 (83.0%) 633 (83.1%) 1262 (83.1%) 0.918
Infants with at least 1 SAE 130 (17.2%) 126 (16.6%) 256 (16.7%) 0.758
Infants with at least 1 SAE judged severe 52 (6.9%) 52 (6.8%) 104 (6.8%) 0.983
Infants with at least 1 SAE judged life threatening 12 (1.6%) 20 (2.6%) 32 (2.1%) 0.156
Infants with at least 1 SAE leading to death 21 (2.8%) 21 (2.8%) 42 (2.8%) 0.990
Infants with an SAE judged possibly related to study drug 2 (0.3%) 2 (0.3%) 4 (0.3%) 1.000
Death 1 (0.1%) 1 (0.1%) 2 (0.1%) —
Alanine aminotransferase increased 0 (0%) 1 (0.1%) 1 (0.1%) —
Neutrophil count decreased 1 (0.1%) 0 (0%) 1 (0.1%) —
Infants with an SAE judged probably related to study drug 0 (0%) 0 (0%) 0 (0%) 1.000
Infants with grade 2B or worse rash 1 (0.1%) 0 (0%) 1 (0.1%) 0.499
No. infants with at least 1 safety laboratory assessment 757 757 1514 —
Abnormal laboratory values*
Infants with any grade neutropenia 458 (60.5%) 442 (58.4%) 900 (59.4%) 0.402
Infants with grade 3 or higher neutropenia 161 (21.3%) 133 (17.7%) 294 (19.4%) 0.069
Infants with any grade anemia 701 (92.6%) 674 (89.0%) 1375 (90.8%) 0.016
Infants with grade 3 or higher anemia 188 (24.8%) 167 (22.1%) 355 (23.4%) 0.203
Infants with any grade ALT concentration 28 (3.7%) 25 (3.3%) 53 (3.5%) 0.678
Infants with grade 3 or higher ALT concentration 4 (0.5%) 3 (0.4%) 7 (0.5%) 1.000
SAE, serious adverse event.
AEs (serious and nonserious) were collected through 8 months, whereas only SAEs were reported after 8 months through 18 months.
Based on 2004 DAIDS Toxicity Tables.
*Some laboratory values were associated with an AE.
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prophylaxis by maternal risk category. Analyses of infection
rates among infants on each study arm and whose mothers
were not on ART were stratified by maternal randomization
CD4 cell counts of ,350 cells per cubic millimeter versus
those whose mothers with $350 cells per cubic millimeter.
Among the 149 mothers (85 whose infants were
randomized to the NVP arm and 64 to the placebo arm) with
CD4 cell counts of ,350 cells per cubic millimeter at ran-
domization and not on ART, the cumulative infection rates
were high, but not statistically different by study arm from 6
through 18 months: 18 months cumulative postnatal infection
rates were 8.9% (95% CI: 2.6% to 15.1%) and 9.6% (95% CI:
2.3% to 17%) in the NVP and placebo arms, respectively (P =
0.87). Likewise, there were no differences between study
arms for this subgroup in 18 HIV infection and/or mortality.
For the 924 women with CD4 cell counts of $350 cells
per cubic millimeter at randomization and not considered
eligible for ART (451 whose infants were randomized to
the NVP arm and 473 whose infants were randomized to
the placebo arm), cumulative postnatal infection risk was
consistently lower in the infant NVP arm than the placebo
arm from 6 through 18 months, although this trend was not
statistically significant. Postnatal transmission risk at 18
months was 1.9% (95% CI: 0.6% to 3.2%) in the NVP arm
and 3.5% (95% CI: 1.8% to 5.2%) in the placebo arm (P =
0.14). Likewise, the overall 18-month risk of HIV infection
and/or death was lower in the NVP arm, 4.8% (95% CI: 2.7%
to 6.8%), compared with 7.2% (95% CI: 4.9% to 9.6%, P =
0.120) in the placebo arm.
Among infants whose mothers were receiving ongoing
ART according to their country guidelines, cumulative post-
natal transmission rates between 6 weeks and 18 months were
uniformly low (0.5%; 95% CI: 0.0% to 1.4%) irrespective of
study arm. The 18-month risk of HIV infection and/or death
was similar in both study arms, 3.7% (95% CI: 1.2% to 6.2%)
in the NVP arm versus 3.8% (95% CI: 1.2% to 6.3%) in the
placebo arm.
We also explored, if there were any differences at 6
through 18 months in HIV transmission and/or death between
infants randomized to the NVP arm born to women with CD4
counts of $350 cells per cubic millimeter not receiving ART
and those infants whose mothers were on ART irrespective of
infant study arm. We found no significant differences in HIV-
free survival comparing these subgroups: the 18-month risk
of HIV infection and/or death was 3.7% (95% CI: 1.9% to
5.5%) versus 4.8% (95% CI: 2.7% to 6.8%; P = 0.460).
Cumulative AEs and Serious Adverse Events
Given high background rates of infectious diseases and
malnutrition at the study sites where the HPTN 046 study was
conducted, clinical AEs were common with 83% of infants in
either arm reporting at least 1 AE by 18 months (Table 2).
Most clinical AEs were mild to moderate in nature; and the
majority of all AEs (94% in each arm) were judged not related
or probably not related to study product. There were no sig-
nificant differences in infant AEs by study arm.
The most common laboratory abnormalities among
infants were decreased hemoglobin (Hb) and neutrophil
counts occurring at least once in 91% and 59% of infants,
respectively, with infants on NVP having a significantly
increased risk of lower Hb (grade 1 or higher, P = 0.016).
Twenty-three percent of infants had at least 1 grade 3 or
higher episode of low Hb, and 19% infants had at least 1
episode of grade 3 or higher neutropenia. In general, these
hematologic laboratory abnormalities were not associated
with symptoms and resolved without intervention. Liver
enzyme alanine aminotransferase (ALT) elevations were
uncommon; 3.7% of infants receiving NVP and 3.3% receiv-
ing placebo had grade 1 or higher ALT elevation. Grade 3 or
4 ALT elevations were rare; 0.5% (NVP) and 0.4% (placebo).
Study product discontinuation was also rare and did not differ
between arms (3% in each arm); the most common reason for
discontinuation was neutropenia.
Infant Deaths
There were 56 infant deaths from age 6 weeks to 18
months, representing an overall infant mortality of 4.3%, with
no statistical differences by study arm (26 deaths—NVP vs.
30 deaths—placebo), with cumulative mortality rates of 4.7%
versus 4.1%, respectively (P = 0.72). The most common
causes of infant mortality were gastroenteritis, pneumonia,
unknown cause, injuries, and anemia.
DISCUSSION
This article presents the final 18-month efficacy and
safety results of HPTN 046, which compared extended infant
daily NVP study product to placebo study product from age 6
weeks to 6 months among HIV-exposed breastfed infants all
of whom received open-label NVP from birth to 6 weeks of
age. As reported earlier, based on HIV transmissions between
6 weeks and 6 months of age, there was a statistically
significant reduction in transmission risk for infants in the
extended NVP arm (1.1%) compared with those in the
placebo arm (2.4%) at the 6-month time point.11 However,
there were no statistical differences in postnatal transmission
rates between study arms for the remainder of the follow-up
period from age 6 months through 18 months, after the infant
prophylaxis had stopped. These results speak to the effective-
ness of infant NVP prophylaxis during the time it was given
during 6 months of breastfeeding but also show this effect
was diluted over time after the infant ARV prophylaxis inter-
vention was stopped.
The HPTN 046 maternal population was reflective of
pregnant women seen in PMTCT programs where the women
were recruited in South Africa, Tanzania, Uganda, and
Zimbabwe. Most were young and had higher CD4 counts
with a median CD4 at baseline of 560 cells per cubic
millimeter. Twenty-nine percent of mothers was on ART
according to their country guidelines at the time of study
randomization. Subgroup analyses indicated very low post-
natal transmission rates (0.5%) for women who were on ART
for their own care throughout the 18 months follow-up.
Also as seen in other studies of extended ARV
prophylaxis used to reduce postnatal transmission,13,14 in
HPTN 046 there were late unexplained transmissions, which
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were detected after reported breastfeeding cessation: 7 of 39
late transmissions were detected subsequent to at least 1 docu-
mented negative infant PCR result, and after maternal re-
ported cessation of breastfeeding. This may have been due
to continued unreported breastfeeding or could be due to as
yet unexplained HIV exposures after breastfeeding cessation.
The cumulative 18-month follow-up rates of postnatal
transmission between 6 weeks and 18 months were encour-
agingly low (2.2% in the NVP arm and 3.1% in the placebo
arm) in this breastfeeding HIV-exposed population, where all
study infants received at least 6 weeks of daily NVP after
birth and were counseled to stop breastfeeding at about 6
months. This postnatal transmission was substantially lower
than reported historical studies in breastfeeding infants before
ARV prophylaxis, where the cumulative overall risk of late
postnatal infection was 8.9 transmissions per 100 child-years
of breastfeeding, with 9.3% cumulative probability of infec-
tion between 4 weeks and 18 months.15
The HPTN 046 study results add to the body of
literature, which supports the effectiveness of extended infant
prophylaxis in reducing the risk of HIV transmission through
breast milk. Although updated guidelines now recommend 12
months of breastfeeding for HIV-exposed infants, the HPTN
046 findings remain relevant in demonstrating the efficacy of
infant NVP prophylaxis for the time it was given during
breastfeeding.
Both extended infant and maternal prophylaxis have
been shown to be effective in reducing postnatal transmission
among women who do not require ART for their own
care.3,4,11 Each approach has advantages and disadvantages.
Maternal triple ARV prophylaxis (eg, option B, option
B+) among women with higher CD4 cell counts decreases
transmission to known noninfected discordant partners based
on recent adult clinical trial data,16 and harmonizes with adult
ART guidelines. Challenges of option B and option B+
include risks of long-term complications with early initiation
of ARVs among asymptomatic women and well-documented
high loss to follow-up and decreased ARV adherence among
HIV-infected pregnant and postpartum women in program-
matic settings.17–20 Poor adherence and loss to follow-up in
turn raise the risk of early emergence of multiclass ARV
resistance among both mothers and their infants who become
infected despite prophylaxis and the risk of increased
transmission.21,22
Infant NVP prophylaxis has the advantages of low cost
while achieving comparable low transmission rates to mater-
nal prophylaxis, lack of risk of multiclass resistance to the
mother or infant and being more forgiving of imperfect
adherence given the long half-life of NVP. In addition, infant
NVP prophylaxis provides an effective postnatal PMTCT
option for mothers who either do not tolerate or refuse
maternal prophylaxis. Acknowledged disadvantages are lack
of impact on horizontal transmission among discordant
partners and lack of benefit for maternal health.
To optimally decrease mother-to-child transmission and
reduce maternal mortality, the highest priority should be to
ensure that women who currently require ART for their own
health receive it.23 When there is an adequate infrastructure to
determine which women require ART, the HPTN 046 find-
ings support the safety and effectiveness of extended infant
NVP prophylaxis in reducing the risk of transmission among
asymptomatic HIV-infected breastfeeding women with higher
CD4 cell counts as long it is maintained throughout the risk
period of breastfeeding. In addition, given its long half-life,
extended infant nevirapine remains an effective option for
those HIV-infected mothers who either cannot tolerate, opt
out or do not adhere to taking maternal ARVs long term.
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